

Evaluation of Protective Role of Ascorbic Acid on Flutamide-Induced Lipid Peroxidation

Supratim Ray

Division of Pharmaceutical Chemistry, Dr. B C Roy College of Pharmacy & Allied Health Sciences, Bidhannagar, Durgapur, 713 206, India.

Corres. Author: supratimray_in@yahoo.co.in
Ph: +91343-2532678, **Telefax:** +91343-2532679

Abstract: The study was designed with an aim to evaluate the antiperoxidative potential of ascorbic acid on flutamide-induced lipid peroxidation. The study was performed *in vitro* using goat liver as lipid source. This evaluation was done by measuring the malondialdehyde and reduced glutathione content of the tissue as markers of lipid peroxidation. The study reveals the lipid peroxidation induction capacity of flutamide and the antiperoxidative potential of ascorbic acid on flutamide-induced lipid peroxidation.

Keywords: lipid peroxidation, flutamide, ascorbic acid, malondialdehyde, reduced glutathione.

Introduction

Free radicals are highly reactive molecules with odd number of electrons. They are constantly being generated in the body through various mechanisms and also being removed by endogenous antioxidant defense mechanism that acts by scavenging free radicals, decomposing peroxides and / or binding with pro-oxidant metal ion (1). Lipid peroxidation leads to generation of peroxides and hydroperoxide that can decompose to yield a wide range of cytotoxic end products most of which are aldehydes as exemplified by malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) etc (2). Free radical mediated oxidative stress results usually from deficient natural antioxidant defense. In case of reduced or impaired defense mechanism and excess generation of free radicals that are not counter balanced by endogenous antioxidant defense exogenously administered antioxidants have been proven useful to overcome oxidative damage (3). So the evaluation of antioxidants as suppressor of drug induced lipid peroxidation provides a scope of further

investigation for their co-administration with drugs to reduce drug-induced toxicities that are possibly mediated by free radical mechanism.

Flutamide, a phototoxic anticancer drug acts as androgen receptor antagonist and used mainly as an anticancer drugs in certain type of prostate cancer. It specifically inhibits androgen uptake and / or nuclear binding of androgen in target tissues. When used as monotherapy, it causes a gradual increase in plasma testosterone due to blockage of feedback inhibition of the hypothalamus and pituitary by testosterone. But it shows a photo hemolytic effect on human erythrocytes and photo induces lipid peroxidation (4).

Ascorbic acid has versatile medicinal properties. It has been now established that besides its own physiological effects it has potential antioxidant property. Ascorbic acid has been reported to have protective role against cadmium induced thyroid dysfunction due to its antioxidant action (5).

The protective effect of various antioxidants on anticancer drug-induced lipid peroxidation had been reported earlier by us (6-8). In continuation of ongoing search for antioxidants, the present work has been carried out *in vitro* to evaluate the antiperoxidative potential of ascorbic acid on flutamide-induced lipid peroxidation.

Experimental

Materials

Thiobarbituric acid (TBA) and trichloroacetic acid (TCA) were purchased from Ranbaxy Fine Chemicals Ltd., New Delhi. 5, 5' dithiobis (2-nitrobenzoic acid) was from SRL Pvt. Ltd., Mumbai. 1,1,3,3, tetraethoxypropane, ascorbic acid and reduced glutathione were from Sigma chemicals Co. St. Louis, MO, USA. All other reagents were of analytical grade. The drug sample (flutamide) was provided by Cipla Ltd. Mumbai, India, Goat liver was used as the lipid source.

Methods

Preparation of tissue homogenate

Goat liver was collected from Drugapur Municipal Corporation (DMC) approved outlet. Goat liver was selected because of its easy availability and close similarity with human liver in its lipid profile (9). Goat liver perfused with normal saline through hepatic portal vein was harvested and its lobes were briefly dried between filter papers to remove excess blood and thin cut with a heavy-duty blade. The small pieces were then transferred in a sterile vessel containing phosphate buffer (pH 7.4) solution. After draining the buffer solution as completely as possible, the liver was immediately grinded to make a tissue homogenate (1 g/ml) using freshly prepared phosphate buffer (pH 7.4). The homogenate was divided into four equal parts, which were then treated differently as mentioned below.

One portion of the homogenate was kept as control (C) while a second portion was treated with the flutamide (D) at a concentration of 0.0125 mg/g tissue homogenate. The third portion was treated with both flutamide at a concentration 0.0125 mg/g tissue homogenate and ascorbic acid at a concentration of 0.166 mg / g tissue homogenate (DA) and the fourth portion was treated only with ascorbic acid at a concentration of 0.166 mg / g tissue homogenate (A). After flutamide and /or ascorbic acid treatment, the liver tissue homogenate samples were shaken for five hours.

Estimation of malondialdehyde (MDA) level from tissue homogenate

The extent of lipid peroxidation was measured in terms of malondialdehyde (MDA) content using thiobarbituric acid (TBA) method (10). The estimation was done at 5 hours of incubation and repeated in five animal sets. In each case three samples of 2.5 ml of incubation mixture were treated with 2.5 ml of 10% (w/v) trichloroacetic acid (TCA) and centrifuged at room temperature at 3000 rpm for 30 minutes to precipitate protein. Then 2.5 ml of the supernatant was treated with 5 ml of 0.002 (M) TBA solutions and then volume was made up to 10 ml with distilled water. The mixture was heated on a boiling water bath for 30 minutes. Then tubes were cooled to a room temperature and the absorbance was measured at 530 nm against a TBA blank (prepared from 5 ml of TBA solution and 5 ml of distilled water) using Shimadzu UV-1700 double beam spectrophotometer. The concentrations of MDA were determined from standard curve, which was constructed as follows. Different aliquots from standard 1, 1, 3, 3-tetrahydroxypropane (TEP) solution were taken in graduated stoppered test tubes and volume of each solution was made up to 5 ml. To each solution, 5 ml of TBA solution was added and the mixture was heated in a steam bath for 30 minutes. The solutions were cooled to a room temperature and their absorbances were measured at 530 nm against TBA as blank. By plotting absorbances against concentrations a straight line passing through the origin of grid was obtained. The best-fit equation is $A=0.007086M$, where M= nanomoles of MDA, A= absorbance, $r = 0.995$, $SEE = 0.006$.

Estimation of reduced glutathione (GSH) level from tissue homogenate:

Reduced glutathione (GSH) was measured in accordance with Ellman's method (11). The estimation was done at 5 hours of incubation and repeated in five animal sets. In each case three samples of 1 ml of incubation mixture were treated with 1 ml of 5% (w/v) TCA in 1 mM EDTA centrifuged at 2000 g for 10 minutes. After that 1 ml of the filtrate was mixed with 5 ml of 0.1M phosphate buffer (pH =8.0) and 0.4 ml of 5, 5'-dithiobis-2-nitrobenzoic acid (0.01% in phosphate buffer pH=8.0) (DTNB) was added to it. The absorbances of the solutions were measured at 412 nm against blank (prepared from 6.0 ml of phosphate buffer and 0.4 ml of DTNB). The concentrations of reduced glutathione were determined from standard curve, which was constructed as follows. Different aliquots of standard reduced

glutathione stock solution were taken in 10 ml volumetric flasks. To each solution 0.4 ml of DTNB solution was added and volume was adjusted up to the mark with phosphate buffer (pH=8.0). The absorbance of each solution was measured at 412 nm against a blank containing 9.6 ml of phosphate buffer (pH=8.0) and 0.4 ml DTNB solution. By plotting absorbances against concentration a straight line passing through the origin of grid was obtained. The best-fit equation was $A = 0.00151C$, where $C =$ nanomoles of reduced glutathione, $A =$ absorbance, $r = 0.997$, $SEE = 0.008$.

Statistical Analysis

Interpretation of the result is supported by student “*t*” test. Analysis of variance (ANOVA) and multiple comparison analysis using least significant different procedure (12, 13) were also performed on the percent changes data of various groups such as flutamide-treated (D), flutamide and ascorbic acid (DA) and only ascorbic acid-treated (A) with respect to control group of corresponding time.

Results & Discussion

The percent changes in MDA and GSH content of different samples at five hours of incubation were calculated with respect to the control of the corresponding time of incubation and was considered as indicator of the extent of lipid peroxidation. The results of the studies on flutamide-induced lipid peroxidation and its inhibition with ascorbic acid were shown in Tables 1-2.

From Table 1 it was evident that tissue homogenates treated with flutamide showed an increase in MDA (9.07 %) content in samples with respect to control to a significant extent. The observations suggest that flutamide could significantly induce the lipid peroxidation process. MDA is a highly reactive three-carbon dialdehyde produced as a byproduct of polyunsaturated fatty acid peroxidation and arachidonic acid metabolism (14). But the MDA (1.17%) content were significantly reduced in

comparison to flutamide-treated group when tissue homogenates were treated with flutamide in combination with ascorbic acid. So the decrease in MDA content of tissue homogenate, when treated with flutamide and ascorbic acid implies the free radical scavenging property of ascorbic acid. Again the tissue homogenates were treated only with the ascorbic acid then the MDA (1.23 %) level were reduced in comparison to flutamide treated group. The increase in MDA content with respect to control when the tissue homogenates were treated with ascorbic acid alone indicates its pro-oxidants effect. It was postulated that ascorbic acid could reduce Fe^{3+} to Fe^{2+} which promotes generation of hydroxyl radicals and other reactive oxygen species through Fenton’s reaction (15, 16). Many known antioxidants like vitamins (17), estrogen (18) superoxide dismutase (19) and flavonoids have been reported to act as pro-oxidant in presence of transition metals (20, 21) or at high concentration.

It was evident from Table 2 that tissue homogenates treated with flutamide caused a decrease in GSH (-9.14%) content with respect control to a significant extent. The decrease in GSH content was associated with an increase in lipid peroxidation. When tissue homogenates were treated both with flutamide and ascorbic acid then the GSH (2.08 %) levels increased in comparison to control and flutamide treated group. Tissue homogenates treated only with ascorbic acid also increase the GSH (3.21%) contents in comparison to the control samples. The increase in GSH level suggests the antiperoxidative potential of ascorbic acid. Glutathione is an important antioxidant and plays a very important role in the defense mechanism for tissue against the reactive oxygen species (22). The depletion of GSH is associated with increase in lipid peroxidation. The decrease in GSH level may be a consequence of enhanced utilization of this compound by the antioxidant enzymes glutathione peroxidase and glutathione-S-transferase.

Table 1: Effects of ascorbic acid on flutamide-induced lipid peroxidation: changes in MDA profile

Name of the antioxidant	Name of the drug	Time of incubation (h)	Animal sets	% Changes in MDA content (with respect to corresponding control) due to treatment with drug and or antioxidant			Analysis of variance and multiple comparison
				Samples			
				D	DA	A	
Ascorbic acid	Flutamide	5	An 1	12.24 ^a	2.12 ^a	1.27 ^d	F1=80.06 [df=(2,8)] F2=2.35 [df=(4,8)] Pooled variance (S ²)*=1.29 Critical difference (p=0.05) [#] LSD =2.14 Ranked means ** (D) (DA, A)
			An 2	7.54 ^a	1.26 ^b	1.16 ^b	
			An 3	7.80 ^a	-1.12 ^a	0.98 ^a	
			An 4	9.52 ^a	2.24 ^b	1.16 ^a	
			An 5	8.24 ^b	1.36 ^a	1.56 ^a	
			Av. (±SEM)	9.07 (±0.86)	1.17 (±0.60)	1.23 (±0.95)	

Percent changes with respect to controls of corresponding hours are shown. C, D, DA & A indicate control (not treated with flutamide or ascorbic acid), only flutamide -treated, flutamide and ascorbic acid-treated and only ascorbic acid-treated samples respectively; Av. = Averages of five animal sets; SEM = Standard error of estimate (df=4); Significant of 't' values of the changes of MDA content (df=2) are shown as: a>99%; b=97.5-99%; c=95-97.5%; d=90-95%; e=80-90%; f=70-80%; g=60-70%; h<60%; Theoretical values of F: p=0.05 level F1=4.46 [df=(2,8)], F2=3.84 [df=(4,8)] P=0.01 level F1=8.65 [df=(2,8)], F2=7.01 [df=(4,8)], F1 and F2 corresponding to variance ratio between groups and within groups respectively; * Error mean square, # Critical difference according to least significant procedure (12, 13) **Two means not included within same parenthesis are statistically significantly different at p=0.05 level.

Table 2: Effects of ascorbic acid on flutamide-induced lipid peroxidation: changes in GSH profile

Name of the antioxidant	Name of the drug	Time of incubation (h)	Animal sets	% Changes in GSH content (with respect to corresponding control) due to treatment with drug and or antioxidant			Analysis of variance and multiple comparison
				Samples			
				D	DA	A	
Ascorbic acid	Flutamide	5	An 1	-8.56 ^b	1.28 ^a	2.54 ^b	F1=150.03 [df=(2,8)] F2=0.24 [df=(4,8)] Pooled variance (S ²)*=1.55 Critical difference (p=0.05) [#] LSD =2.34 Ranked means ** (D) (DA, A)
			An 2	-10.26 ^a	2.54 ^b	3.26 ^b	
			An 3	-11.26 ^b	2.88 ^a	4.12 ^a	
			An 4	-7.52 ^a	1.24 ^b	2.56 ^b	
			An 5	-8.12 ^b	2.48 ^b	3.56 ^a	
			Av. (±SEM)	-9.14 (±0.69)	2.08 (±0.34)	3.21 (±0.30)	

Percent changes with respect to controls of corresponding hours are shown. C, D, DA & A indicate control (not treated with flutamide or ascorbic acid), only flutamide -treated, flutamide and ascorbic acid-treated and only ascorbic acid-treated samples respectively; Av. = Averages of five animal sets; SEM = Standard error of estimate (df=4); Significant of 't' values of the changes of GSH content (df=2) are shown as: a>99%; b=97.5-99%; c=95-97.5%; d=90-95%; e=80-90%; f=70-80%; g=60-70%; h<60%; Theoretical values of F: p=0.05 level F1=4.46 [df=(2,8)], F2=3.84 [df=(4,8)] P=0.01 level F1=8.65 [df=(2,8)], F2=7.01 [df=(4,8)], F1 and F2 corresponding to variance ratio between groups and within groups respectively; * Error mean square, # Critical difference according to least significant procedure (12, 13) **Two means not included within same parenthesis are statistically significantly different at p=0.05 level.

To compare means of more than two samples, multiple comparison analysis along with analysis of variance was performed on the percent changes data with respect to control of corresponding hours. It is seen that there is significant differences among various groups (F1) such as flutamide-treated, flutamide and ascorbic acid-treated and only ascorbic acid-treated. But within a particular group, differences (F2) are insignificant which shows that there is no statistical difference in animals in a particular group (Tables 1-2). The Tables also indicate that the level of MDA / GSH in flutamide -treated group is only statistically significantly different from the flutamide and ascorbic acid -treated group as well as only ascorbic acid-

treated group. But there is no statistically significantly difference among the flutamide and ascorbic acid-treated group and only ascorbic acid-treated group.

Conclusion

The results suggest the antiperoxidative effects of ascorbic acid and demonstrate its potential to reduce flutamide-induced lipid peroxidation and thus to increase therapeutic index of the drug by way of reducing toxicity that may be mediated through free radical mechanisms. However a detailed study is required to conclude such hypothesis.

References

- Gutteridge J.M.C. and Halliwell B., Free radicals and antioxidants in the year 2000. A historical look to the future, *Ann. N. Y. Acad. Sci.*, 2000, 899, 136-147.
- Esterbauer H., Zollner H. and Schauer R.J., Hydroalkenals: Cytotoxic products of lipid peroxidation, *Atlas Sci Biochem.*, 1998, 1, 311-319.
- Halliwell B., Drug antioxidant effects -A basis for drug selection? *Drugs*, 1991, 42, 569-605.
- Vargas F., Rivas C., Méndez H., Fuentes A., Fraile G. and Velásquez M., Photochemistry and phototoxicity studies of flutamide, a phototoxic anti-cancer drug, *J. Photochem. Photobiol. B*, 2000, 58, 108-114.
- Gupta P. and Kar A., Role of ascorbic acid in cadmium-induced thyroid dysfunction and lipid peroxidation, *J. Appl. Toxicol.* 1998, 18, 317-320.
- Ray S., Roy K. and Sengupta C., Evaluation of protective effects of ascorbic acid (blue green algae) on Cisplatin- induced lipid peroxidation, *Indian. J. Pharm. Sci.*, 2007, 69, 378-383.
- Ray S., Roy K. and Sengupta C., *In vitro* evaluation of protective effects of ascorbic acid and water extract of *Spirulina plentesis* (blue green algae) on 5-fluorouracil-induced lipid peroxidation, *Acta Pol. Pharm. Drug Res.*, 2007, 64, 335-344.
- Ray S., Roy K. and Sengupta C., Exploring the protective effect of ascorbic acid and ascorbic acid (blue green algae) on methotrexate-induced lipid peroxidation, *Iranian J. Pharm. Sci.*, 2007, 3, 217-218.
- Hilditch T.P. and Williams P.N., *The Chemical Constituents of Fats*, Chapman & Hall, London, 1964, 100.
- Ohkawa H., Ohishi N. and Yagi K., Assay of lipid peroxidation in animal tissue by thiobarbituric acid reaction, *Anal. Biochem.*, 1979, 95, 351-358.
- Ellman G.L., Tissue sulfhydryl groups, *Arch. Biochem. Biophys.*, 1959, 82, 70-77.
- Snedecor G.W. and Cochran W.G., *Statistical Methods*, Oxford & IBH Publishing Co. Pvt. Ltd., New Delhi, 1967, 375.
- Bolton S., *Statistics*, in Gennaro A.R., (Ed.), *Remington: The Science and Practice of Pharmacy*, Lippincott Williams & Wilkins, Philadelphia, 2000, 124-158.
- Winrow V.R., Winyard P.G., Morris C.J. and Black, D.R., Free radicals in inflammation: second messengers and mediators of tissue destruction, *Br. Med. Bull.*, 1993, 49, 506-522.
- Dennis R.F., Larry M.H., Howard A.I.N. and Donald T.W., *Principle of Medicinal Chemistry*, 4th edition, Waverly Pvt.Ltd., New Delhi, 1995, 523-535.
- Halliwell B. and Gutteridge J.M.C., Role of free radicals and catalytic metal ions in human disease: an overview, *Methods Enzymol.*, 1990, 186, 1-85.
- Herbert V., Prooxidant effects of antioxidant vitamins. Introduction, *J. Nutr.*, 1996, 126, 1197-1202.
- Kose K., Dogan P. and Ozesmi P., Contraceptive steroids increase erythrocyte lipid peroxidation in female rats, *Contraception*, 1993, 47, 421-425.
- Offer T., Russo A. and Samuni A., The pro-oxidative activity of SOD and nitroxide SOD mimics, *FASEB*, 2000, 14, 1215-1223.

20. Hodnick W.F., Ahmad S. and Pardini R.S., Induction of oxidative stress by redox active flavonoids, *Adv. Exp. Med. Biol.*, 1998, 439, 131-144.
21. Halliwell B., Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?, *Lancet*, 1994, 344, 721-724.
22. Kosower E.M. and Kosower N.S., *Glutathione Metabolism and Function*, Raven Press, New York, 1976, 133.
